Contura
HomePage - Contura | Hydrogels for life.
| GBP | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (10 %) | (39 %) | (12 %) | 13 % | 19 % | 53 % | (28 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 11 % | (2 %) | 5 % | - | - | 1 % | 8 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (4 %) | (84 %) | 89 % | (7 %) | 17 % | (10 %) | 144 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Contura is a pioneering company specializing in the development and manufacturing of injectable polyacrylamide hydrogels, particularly the patented 2.5 iPAAG. This hydrogel, composed of 2.5% cross-linked polyacrylamide and 97.5% water, is designed to provide long-lasting symptom relief and improved joint function for both humans and animals suffering from various conditions, including osteoarthritis. The company operates in the healthcare market, serving both medical and veterinary clients. Contura's business model revolves around the research, development, and commercialization of its unique hydrogel products. Revenue is generated through the sale of these specialized hydrogels to healthcare providers and veterinary clinics. The company is committed to meeting and exceeding regulatory quality standards, ensuring that their products are safe and effective for their intended uses.
Keywords: hydrogel, polyacrylamide, osteoarthritis, joint pain, veterinary, medical, injectable, non-degradable, bio scaffold, symptom relief.